Owkin appoints biotech leader Andreas Emmenegger as Chief Financial Officer
Andreas will manage investor relations, fundraising and financial strategy at Owkin, supporting its mission of using AI to find the right treatment for every patient.
Andreas has more than 20 years of experience as the CFO of public and private multinational companies, including 15 years in the biotech industry. Andreas was CFO of Swiss biopharma company Molecular Partners from 2007 to 2022, where he led the capital raising in private and public equity and IPOs on the SIX Swiss Exchange in 2014 and on the Nasdaq in 2021. Prior to this, he was CFO of Glycart Biotechnology AG, Head of Strategic Alliance Finance (Genentech) for Roche. Since 2016, Andreas has been a member of the board of directors of the Luzerner Kantonalbank, a publicly listed Swiss bank.
Thomas Clozel, Co-founder and CEO of Owkin, said:
I am excited to work with Andreas to further unleash the power of Owkin’s world-leading AI and data expertise to benefit patients and doctors. His decades of experience at the top of biotech and finance will help us to achieve our mission of finding the right treatment for every patient.
Andreas Emmenegger, Chief Financial Officer at Owkin, said:
I am thrilled to join Owkin's leadership team and to contribute to building the world's premier AI biotech. I am impressed by their unrivalled power of collective intelligence with its innovative de-centralized data infrastructure that has the potential to revolutionize drug development in terms of speed, costs and, most importantly, patient benefit.
Together with the Owkin team, I look forward to helping the company create long term value for investors, healthcare providers and patients, always true to its culture and mission.
Authors
About Owkin
Owkin is the first full-stack TechBio company on a mission to understand complex biology and derive new multimodal biomarkers through AI.
We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular, immunity and inflammation.
Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across seven cancer indications.
Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like Fidelity, GV and Bpifrance, among others.
